JP2014520120A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014520120A5 JP2014520120A5 JP2014516044A JP2014516044A JP2014520120A5 JP 2014520120 A5 JP2014520120 A5 JP 2014520120A5 JP 2014516044 A JP2014516044 A JP 2014516044A JP 2014516044 A JP2014516044 A JP 2014516044A JP 2014520120 A5 JP2014520120 A5 JP 2014520120A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- amino acids
- substituted
- polypeptide
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001413 amino acids Chemical class 0.000 claims 42
- 108090000765 processed proteins & peptides Proteins 0.000 claims 30
- 229920001184 polypeptide Polymers 0.000 claims 26
- 102000004196 processed proteins & peptides Human genes 0.000 claims 26
- 229910052799 carbon Inorganic materials 0.000 claims 14
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 10
- 125000003342 alkenyl group Chemical group 0.000 claims 7
- 125000000217 alkyl group Chemical group 0.000 claims 7
- 125000005647 linker group Chemical group 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 claims 4
- 125000004450 alkenylene group Chemical group 0.000 claims 3
- 125000002947 alkylene group Chemical group 0.000 claims 3
- 125000000304 alkynyl group Chemical group 0.000 claims 3
- 125000004419 alkynylene group Chemical group 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical group N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims 2
- 238000004132 cross linking Methods 0.000 claims 2
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 2
- 125000001475 halogen functional group Chemical group 0.000 claims 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 2
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 229940063675 spermine Drugs 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 claims 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 101710149951 Protein Tat Proteins 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 239000007801 affinity label Substances 0.000 claims 1
- 239000011616 biotin Chemical group 0.000 claims 1
- 229960002685 biotin Drugs 0.000 claims 1
- 235000020958 biotin Nutrition 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 150000002009 diols Chemical class 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 150000004665 fatty acids Chemical group 0.000 claims 1
- 239000007850 fluorescent dye Substances 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- OOYGSFOGFJDDHP-KMCOLRRFSA-N kanamycin A sulfate Chemical group OS(O)(=O)=O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N OOYGSFOGFJDDHP-KMCOLRRFSA-N 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 150000003553 thiiranes Chemical class 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161498477P | 2011-06-17 | 2011-06-17 | |
| US61/498,477 | 2011-06-17 | ||
| PCT/US2012/042719 WO2012174409A1 (en) | 2011-06-17 | 2012-06-15 | Stabilized variant maml peptides and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014520120A JP2014520120A (ja) | 2014-08-21 |
| JP2014520120A5 true JP2014520120A5 (enExample) | 2015-07-30 |
Family
ID=47357495
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014516044A Pending JP2014520120A (ja) | 2011-06-17 | 2012-06-15 | 安定化した変異型ｍａｍｌペプチドおよびその使用 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20140256912A1 (enExample) |
| EP (1) | EP2721061A4 (enExample) |
| JP (1) | JP2014520120A (enExample) |
| WO (1) | WO2012174409A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7192713B1 (en) | 1999-05-18 | 2007-03-20 | President And Fellows Of Harvard College | Stabilized compounds having secondary structure motifs |
| PT2332968T (pt) | 2003-11-05 | 2016-08-17 | Harvard College | Péptidos alfa-helicoidais adequados para a activação ou inibição da morte celular |
| EP3159352B1 (en) | 2007-03-28 | 2023-08-02 | President and Fellows of Harvard College | Stitched polypeptides |
| WO2010011313A2 (en) | 2008-07-23 | 2010-01-28 | President And Fellows Of Harvard College | Ligation of stapled polypeptides |
| JP2012515172A (ja) | 2009-01-14 | 2012-07-05 | エルロン・セラピューティクス・インコーポレイテッド | ペプチド模倣大環状分子 |
| WO2011008260A2 (en) | 2009-07-13 | 2011-01-20 | President And Fellows Of Harvard College | Bifunctional stapled polypeptides and uses thereof |
| AU2010298338A1 (en) | 2009-09-22 | 2012-04-12 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
| KR102104762B1 (ko) | 2010-08-13 | 2020-04-24 | 에일러론 테라퓨틱스 인코포레이티드 | 펩티도미메틱 거대고리 |
| WO2012174423A1 (en) | 2011-06-17 | 2012-12-20 | President And Fellows Of Harvard College | Stabilized polypeptides as regulators of rab gtpase function |
| TW201806968A (zh) | 2011-10-18 | 2018-03-01 | 艾利倫治療公司 | 擬肽巨環化合物 |
| CA2864120A1 (en) | 2012-02-15 | 2013-08-22 | Aileron Therapeutics, Inc. | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles |
| NZ627528A (en) | 2012-02-15 | 2016-05-27 | Aileron Therapeutics Inc | Peptidomimetic macrocycles |
| EP2920197B1 (en) | 2012-09-26 | 2021-03-17 | President and Fellows of Harvard College | Proline-locked stapled peptides and uses thereof |
| BR112015009470A2 (pt) | 2012-11-01 | 2019-12-17 | Aileron Therapeutics Inc | aminoácidos dissubstituídos e seus métodos de preparação e uso |
| EP2991665A4 (en) | 2013-03-13 | 2016-11-09 | Harvard College | STACKED AND GRAFTED POLYPEPTIDES AND USES THEREOF |
| US10308926B2 (en) | 2013-03-15 | 2019-06-04 | Dana-Farber Cancer Institute, Inc. | Stablized EZH2 peptides |
| KR20160019547A (ko) | 2013-06-14 | 2016-02-19 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 안정화된 폴리펩티드 인슐린 수용체 조절제 |
| CN111620940A (zh) | 2014-05-21 | 2020-09-04 | 哈佛大学的校长及成员们 | Ras抑制肽和其用途 |
| MX389354B (es) | 2014-09-24 | 2025-03-20 | Aileron Therapeutics Inc | Macrociclos peptidomimeticos y formulaciones de los mismos. |
| KR20170058424A (ko) | 2014-09-24 | 2017-05-26 | 에일러론 테라퓨틱스 인코포레이티드 | 펩티드모방 거대고리 및 이의 용도 |
| SG11201707750YA (en) | 2015-03-20 | 2017-10-30 | Aileron Therapeutics Inc | Peptidomimetic macrocycles and uses thereof |
| WO2017004548A1 (en) | 2015-07-01 | 2017-01-05 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
| US10023613B2 (en) | 2015-09-10 | 2018-07-17 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles as modulators of MCL-1 |
| US20190135868A1 (en) * | 2016-04-29 | 2019-05-09 | The University Of Chicago | Synthetic dna binding domain peptides and uses thereof |
| KR20200064075A (ko) | 2017-09-07 | 2020-06-05 | 포그 파마슈티컬스 인코포레이티드 | 베타-카테닌 기능을 조절하는 제제 및 이의 방법 |
| WO2019136209A1 (en) * | 2018-01-05 | 2019-07-11 | President And Fellows Of Harvard College | Stabilized polypeptides and uses thereof |
| CN113039195A (zh) | 2018-08-20 | 2021-06-25 | 弗格制药有限公司 | 肽集合、肽试剂及其使用方法 |
| EP4600411A3 (en) | 2019-04-09 | 2025-09-10 | The University of Chicago | Versatile peptide and protein macrocyclization and multimerization with diels-alder cycloadditions |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2091552A4 (en) * | 2006-11-15 | 2010-01-06 | Dana Farber Cancer Inst Inc | STABILIZED MAML-PEPTIDES AND ITS USES |
| AU2009294877C1 (en) * | 2008-09-22 | 2015-05-07 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
| AU2009294872A1 (en) * | 2008-09-22 | 2010-03-25 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
-
2012
- 2012-06-15 JP JP2014516044A patent/JP2014520120A/ja active Pending
- 2012-06-15 EP EP12800679.8A patent/EP2721061A4/en not_active Withdrawn
- 2012-06-15 US US14/127,039 patent/US20140256912A1/en not_active Abandoned
- 2012-06-15 WO PCT/US2012/042719 patent/WO2012174409A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014520120A5 (enExample) | ||
| JP2010518017A5 (enExample) | ||
| JP2014224121A5 (enExample) | ||
| ES2876939T3 (es) | Péptidos penetradores de células que tienen un dominio hidrófobo central | |
| CO2020001113A2 (es) | Muteínas de interleucina 21 y métodos de tratamiento | |
| JP2011502964A5 (enExample) | ||
| JP2010532168A5 (enExample) | ||
| CA2862391C (en) | Stabilized antiviral fusion helices | |
| RU2016146198A (ru) | Терапевтические dll4-связывающие белки | |
| RU2017134456A (ru) | Рекомбинантные связывающие белки и их применение | |
| JP2018508492A5 (enExample) | ||
| JP2014534220A5 (enExample) | ||
| JP2015522576A5 (enExample) | ||
| JP2018015005A5 (enExample) | ||
| JP2006512300A5 (enExample) | ||
| CY1116011T1 (el) | Hla-a*1101-περιορισμενο wt1 πεπτιδιο και φαρμακευτικη συνθεση που το περιλαμβανει | |
| PE20210376A1 (es) | Peptidos y combinacion de peptidos de origen no canonico para el uso en la inmunoterapia contra diferentes tipos de cancer | |
| JP2012505657A5 (enExample) | ||
| JP2015526434A5 (enExample) | ||
| JP2006506942A5 (enExample) | ||
| RU2016130448A (ru) | Пептидные дендримеры, содержащие фибриноген-связывающие пептиды | |
| JP2016535058A5 (enExample) | ||
| JP2014526881A5 (enExample) | ||
| MX2021004714A (es) | Proteina cas9 modificada, y uso de la misma. | |
| JP2020514299A5 (enExample) |